Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A PHASE 3 PROTOCOL TO EVALUATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF RESPIRATORY SYNCYTIAL VIRUS (RSV) PREFUSION F SUBUNIT VACCINE IN ADULTS AT HIGH RISK OF SEVERE RSV DISEASE

NCT05842967 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT05842967
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05842967 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A PHASE 3 PROTOCOL TO EVALUATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF RESPIRATORY SYNCYTIAL VIRUS (RSV) PREFUSION F SUBUNIT VACCINE IN ADULTS AT HIGH RISK OF SEVERE RSV DISEASE
Lead sponsor
Pfizer
Phase
Phase 3
Overall status
Completed
Start date
May 11, 2023
Completion date
March 18, 2024
Enrollment
885 (actual)
Sites
36

Conditions

As the registry lists them; a condition with its own page is linked.

respiratory syncytial virus (rsv)